Abstract:Background and Purpose— A large number of traditional Chinese patent medicine (TCPM) are widely used for ischemic stroke in China. The aim of this study was to systematically review the existing clinical evidence on TCPM for ischemic stroke. Methods— We identified all TCPM that were listed in the Chinese National Essential Drug list of 2004 and those commonly used TCPM in current clinical practice for ischemic stroke. Fifty-nine TCPM were identified for further evaluation. We applied Cochrane systematic review methods. We searched for reports of randomized controlled trials and controlled clinical trials on any of the 59 TCPM for ischemic stroke comparing one TCPM with control. Primary outcomes included death or dependency at the end of follow-up (at least 3 months) and adverse events. Effects on neurological impairments were a secondary outcome. Results— One-hundred ninety-one trials (19 338 patients) on 22 TCPM were available and included, of which 120 were definite or possible randomized controlled trials and 71 were controlled clinical trials. The methodological quality of included trials was generally “poor.” Few trials reported methods of randomization. Three trials were randomized, double blind, and placebo-controlled. Primary outcomes: one trial on Puerarin and one trial on Shenmai injection assessed death or dependency at the end of long-term follow-up (at least 3 months) and found no statistically significant difference between 2 groups. The reported adverse events including allergic reaction, headache, nausea, diarrhea, bellyache, blood pressure change, and subcutaneous ecchymosis. Most of the adverse events were not severe. Secondary outcomes: analysis of the secondary outcome, “marked improvement in neurological deficit,” showed apparent benefits of about the same magnitude for all the TCPM studied. Of the 22 TCPM, 8 drugs (Milk vetch, Mailuoning, Ginkgo biloba, Ligustrazine, Danshen agents, Xuesetong, Puerarin, and Acanthopanax) had relatively more studies and patient numbers. Conclusions— There was insufficient good quality evidence on the effects of TCPM in ischemic stroke on the primary outcome (death or dependency). We considered the apparent benefit on neurological impairment was as likely to be attributable to bias from poor methodology as to a real treatment effect. However, because the agents assessed appeared potentially beneficial and nontoxic, further randomized controlled trials are justified. Eight drugs could be further research priorities.

Network Meta-Analysis: Aspirin Plus Traditional Chinese Medicine for Stroke Prevention in Patients with Atrial Fibrillation

Randomized Study of Efficiency and Safety of Antithrombotic Therapy with Warfarin in Nonvalvular Atrial Fibrillation

Efficacy and Safety of Traditional Chinese Medicine on Thromboembolic Events in Patients with Atrial Fibrillation: A Systematic Review and Meta-Analysis

Clinical study of cerebral infarction prevention with warfarin in nonvalvular atrial fibrillation

[The Randomized Study of Efficiency and Safety of Antithrombotic Therapy in Nonvalvular Atrial Fibrillation: Warfarin Compared with Aspirin].

Meta-analysis on the Efficacy and Adverse Events of Aspirin Plus Clopidogrel Versus Aspirin-Mono-therapy in Patients with Ischemic Stroke or Transient Ischemic Attack

Anticoagulant and Antiplatelet therapy for the prevention of stroke in AF with arterial origin stroke: a meta-analysis.

Comparative effectiveness and safety of four traditional Chinese medicine injections with invigorating blood circulation, equivalent effect of anticoagulation or antiplatelet in acute myocardial infarction: a Bayesian network meta-analysis

Traditional Chinese Medicine For Acute Coronary Syndrome A Meta-Analysis Of Clinical Manifestations And Objective Indicators

Effectiveness and Safety ofBlending Traditional Chinese Medicine with Western Medicine for Enhanced Secondary Stroke Prevention: AMeta-Analysis of RCTs

Efficacy and Safety of Anticoagulant Therapy Versus Antiplatelet Therapy in Acute Ischemic Stroke Patients with Atrial Fibrillation

Comparative efficacy and safety of traditional Chinese medicine injections in patients with transient ischemic attack: A systematic review and network meta-analysis

Comparative efficacy and safety of Chinese patent medicines of acute ischemic stroke: A network meta-analysis

Comprehensive systematic review and meta-analysis on anticoagulants and aspirin for stroke prevention in non-valvular atrial fibrillation patients.

Meta-analysis of Efficacy and Safety of the New Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation.

Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation

Clinical Efficacy of the Huo Xue Hua Yu Method Combined with Aspirin in the Treatment of Acute Cerebral Infarction: A systematic evaluation and Meta-Analysis

Clinical Outcomes of Antithrombotic Strategies for Patients with Atrial Fibrillation after Percutaneous Coronary Intervention

Percutaneous or surgical LAAO for stroke prevention in patients with atrial fibrillation: A network meta-analysis

Low-Molecular-Weight Heparin Versus Aspirin in Early Management of Acute Ischemic Stroke: A Systematic Review and Meta-Analysis

Meta-Analysis of Traditional Chinese Patent Medicine for Ischemic Stroke